Quality control in the regulation of pharmaceuticals Alan Maynard Editorial 17 September 2012 Pages: 421 - 422
Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder Ellen W. Freeman Current Opinion 17 September 2012 Pages: 433 - 444
Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? Adam La Caze Commentary 17 September 2012 Pages: 445 - 447
Valuing patient and caregiver time Jennifer E. TranmerDenise N. GuerrierePeter C. Coyte Review Article 17 September 2012 Pages: 449 - 459
The health-related quality of life and economic burden of constipation Cheryl DennisonManishi PrasadKarin Coyne Review Article 17 September 2012 Pages: 461 - 476
Economic considerations in the prescribing of third-generation antidepressants Stuart MontgomeryJohn J. DoyleChristopher R. McBurney Review Article 17 September 2012 Pages: 477 - 491
Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Lucie BlaisOdile SheehyJacques LeLorier Original Research Article 17 September 2012 Pages: 493 - 503
Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy Ernst BerndtJoel KallichJohn Glaspy Original Research Article 17 September 2012 Pages: 505 - 514
Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia Kim DalzielAli RoundKen Stein Original Research Article 17 September 2012 Pages: 515 - 526
On pharmacogenomics and cost-effectiveness analysis at the individual level Mohan V. BalaGary A. Zarkin Correspondence 17 September 2012 Pages: 527 - 527
